Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daylight photodynamic therapy with methyl aminolevulinate vs cryosurgery for actinic keratoses of the face
2014-005121-13Phase 4Completed
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Feb 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of methyl aminolevulinate in actinic keratosis (AK) and photoaging (2 arms), sponsored by Universitätsklinikum Regensburg. Primary endpoint: Cumulative number of actinic keratosis lesions. Started Feb 2015; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)photoaging
Beyond the preview
Go deeper on 2014-005121-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005121-13.